bioRxivBioinformaticsPreprint
The discovery of potential natural products for targeting SARS-CoV-2 spike protein by virtual screening
Guanyu CheniD, Tsung-You Yao, Azaj AhmediD, Yi‐Cheng PaniD, Juan‐Cheng YangiD, Yang‐Chang WuiD
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters into the cells through its spike proteins binding to human angiotensin-converting enzyme 2 (ACE2) protein and causes virus infection in host cells. Until now, there are no available antiviral drugs have been reported that can effectively block virus infection. The study aimed to discover the potential compounds to prevent viral spike proteins to bind to the human ACE2 proteins from Taiwan Database of Extracts and Compounds (TDEC) by structure-based virtual screening. In this study, to rapidly discover potential inhibitors against SARS-CoV-2 spike proteins, the molecular docking calculation was performed by AutoDock Vina program. Herein, we found that 39 potential compounds may have good binding affinities and can respectively bind to the viral receptor-binding domain (RBD) of spike protein in the prefusion conformation and spike-ACE2 complex protein in silico. Among those compounds, especially natural products thioflexibilolide A and candidine that were respectively isolated from the soft corals Sinularia flexibilis and Phaius mishmensis may have better binding affinity than others. This study provided the predictions that these compounds may have the potential to prevent SARS-CoV-2 spike protein from entry into cells.
- organism: human
- research focus: drug response / drug discovery
- research focus: differential expression
- approach: statistical model
- approach: simulation
- Citations
- 8
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A repurposed drug screen identifies compounds that inhibit the binding of the COVID-19 spike protein to ACE2
K. B. Tsegay, C. M. Adeyemi, … S. E. P. Smith·bioRxiv·Apr 8, 2021
- Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2
C. Li, H. Zhou, … C.-N. Qian·bioRxiv·Dec 14, 2021
- Deep learning-based Drug discovery of Mac domain of SARS-CoV-2 (WT) Spike inhibitors: using experimental ACE2 Inhibition TR-FRET Assay Screening and Molecular Dynamic Simulations.
Saleem Iqbal, Sheng-Xiang-Lin·bioRxiv·Oct 17, 2022
- Computational Design of Peptides to Block Binding of the SARS-CoV-2 Spike Protein to Human ACE2
Xiaoqiang Huang, Robin Pearce, Yang Zhang·AgingPeer-reviewed·Jun 16, 2020
- Computational analysis on the ACE2-derived peptides for neutralizing the ACE2 binding to the spike protein of SARS-CoV-2
c. s. lupala, V. Kumar, … h. liu·bioRxiv·May 3, 2020
- Molecular dynamics simulations and functional studies reveal that hBD-2 binds SARS-CoV-2 spike RBD and blocks viral entry into ACE2 expressing cells
L. Zhang, S. K. Ghosh, … A. Weinberg·bioRxiv·Jan 7, 2021